NEW
YORK and SYDNEY, Jan. 25, 2022 – PRESS RELEASE – Tilray Brands Inc.,
a leading global cannabis-lifestyle and consumer packaged goods company
inspiring and empowering the worldwide community to live its very best life, announced
the expansion of its medical cannabis product offering in Australia and a new
medical cannabis e-learning platform for health care providers.
Denise
Faltischek, head of international and chief strategy officer, said, “Tilray is
transforming the industry globally with our highly scalable footprint and
portfolio of diverse cannabis products. As medical cannabis demand increases
worldwide, we remain committed to providing health care professionals and
patients with safe and reliable access to the highest-quality medical cannabis
products.”
Faltischek
added, “After listening to patient feedback and leveraging learnings from our
operations in Germany, we are excited to be introducing new products in
Australia that meet consumer needs.”
Tilray's product
offering in Australia approved under the Therapeutic Goods
Administration (TGA) Special Access and Authorized Prescriber Scheme is
centered around its whole flower options ranging from balanced 1:1 whole flower
(THC 10, CBD 10), including mid-range (17), and high-THC (25) varieties of 15g
bag GMP-certified medical cannabis whole flower.
George
Polimenakos, general manager, Tilray Australia and New Zealand, said, "We
are committed to providing reliable access to patients in need with
pharmaceutical-grade medical cannabis products and are pleased to be expanding
our medical cannabis offerings in Australia."
Polimenakos
added, “On a related note, cannabis education is paramount to everything we do,
and [we] are therefore excited to offer health care professionals with the
tools they need to learn about cannabis through our new e-learning platform.”
Tilray’s
new medical cannabis educational platform for health care professionals is
built on the importance of understanding the benefits derived from medical
cannabis use. To date, Tilray has successfully introduced multiple medical
cannabis workshops across Australia and New Zealand, educating hundreds of
health care practitioners in 2021.
In
addition to supplying hospitals and pharmacies, Tilray is a proud
partner with several leading research institutions, including the Murdoch
Children's Research Institute in Australia, studying the
effectiveness of Tilray medical cannabis as a treatment for pediatric
patients with Intellectual Disabilities suffering from Severe Behavioral
Problems; a clinical trial in partnership with The Government of New South
Wales and University of Sydney Chris O'Brien Lifehouse to
develop a novel treatment for chemotherapy-induced nausea, and a study led by
the University of Sydney examining the effects of driving under the
influence of cannabis.
Today,
Tilray is one of the leading providers of GMP-certified medical cannabis to
patients, physicians, pharmacies, hospitals, governments, and researchers
across the globe.
For more
information about Tilray medical cannabis in Australia and New Zealand, visit: https://www.tilray.com.au/
For more
information about the Tilray medicinal cannabis workshops in Australia, visit: https://tilray.medihuanna.com/
